Shenzhen Vital New Material (301319.SZ) plans to launch a stock option and restricted stock incentive plan in 2026.
Weiteou (301319.SZ) has disclosed the draft of its stock option and restricted stock incentive plan for 2026. This incentive plan aims to grant 1.04 million stock options and 260,000 restricted shares to the incentive recipients, with a total grant of 1.3 million options/shares, accounting for approximately 0.7125% of the company's total share capital at the time of the announcement of the draft plan. Among these, 1.04 million options/shares will be granted initially, and 260,000 options/shares are reserved. The exercise price for the stock options (including the reserved portion) is set at 90.83 yuan per option, while the grant price for the restricted shares (including the reserved portion) is set at 45.42 yuan per share. A total of 108 individuals are proposed as the initial recipients of the incentive.
Shenzhen Vital New Material (301319.SZ) has disclosed its draft stock option and restricted stock incentive plan for 2026. This incentive plan intends to grant a total of 1.04 million stock options and 260,000 shares of restricted stock to the incentivized parties, totaling 1.3 million rights/shares, which accounts for approximately 0.7125% of the company's total equity at the time of the draft announcement. Among these, 1.04 million rights/shares will be granted initially; 260,000 rights/shares will be reserved. The exercise price for the stock options (including reserved portions) is set at 90.83 yuan per option, while the grant price for the restricted stock (including reserved portions) is set at 45.42 yuan per share. A total of 108 individuals are proposed to be the initial incentivized parties.
Related Articles

Huaan Fund Management Co., Ltd. increased its holding in KEYMED BIO-B (02162) by 203,500 shares at an average price of approximately HKD 72.88 per share.

GIC Private Limited has increased its holdings in ABBISKO-B (02256) by 129,000 shares at a price of approximately HKD 9.67 per share.

Apple Inc. (AAPL.US) annual sales in India have surpassed $10 billion for the first time: iPhone leads revenue growth, and the "new growth engine" is accelerating its formation.
Huaan Fund Management Co., Ltd. increased its holding in KEYMED BIO-B (02162) by 203,500 shares at an average price of approximately HKD 72.88 per share.

GIC Private Limited has increased its holdings in ABBISKO-B (02256) by 129,000 shares at a price of approximately HKD 9.67 per share.

Apple Inc. (AAPL.US) annual sales in India have surpassed $10 billion for the first time: iPhone leads revenue growth, and the "new growth engine" is accelerating its formation.

RECOMMEND





